OSE Immunotherapeutics : to Host an 'Immuno-Oncology R&D Day' On October 12th, 2021

Nantes, France - OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced that it will host a virtual and in-person R&D Day on Tuesday, October 12th, 2021 at 4:00 p.m. CEST/ 10:00 a.m. EDT, being hosted in Paris.

The event, which will feature presentations by leading clinicians as well as key members of the OSE Immunotherapeutics management team, will provide an update on: * The Company's strategy to build a leading portfolio of best- and first-in-class cancer immunotherapies. * OSE's goal to position Tedopi as a new standard of care in non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure and its ongoing clinical development as a maintenance therapy for ovarian and pancreatic cancers. * Recent clinical data supporting development of first-in-class CD47/SIRP? pathway targeting antibody BI 765063 alone and in combination with anti-PD-1 ezabenlimab in solid tumours. * OSE's emerging best- and first-in-class immuno-oncology portfolio which includes a novel myeloid cell 'Don't Eat Me' signal targeting CLEC-1 and a bispecific antibody platform (BiCKI) whose first candidate, BiCKI-IL-7 both combines an anti-PD-1 and the cytokine signal interleukin-7 (IL-7).

Contact:

Investor

Thomas Guillot

E: [e-mail]

T: [phone]

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2021, including the annual financial report for the fiscal year 2020, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

(C) 2021 Electronic News Publishing, source ENP Newswire